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High-throughput immuno-profiling 
of mamba (Dendroaspis) venom 
toxin epitopes using high-density 
peptide microarrays
Mikael Engmark1,2, Mikael R. Andersen2, Andreas H. Laustsen2,3, Jigar Patel4, Eric Sullivan4, 
Federico de Masi1, Christian S. Hansen1, Jens V. Kringelum1, Bruno Lomonte5, 
José María Gutiérrez5 & Ole Lund1
Snakebite envenoming is a serious condition requiring medical attention and administration of 
antivenom. Current antivenoms are antibody preparations obtained from the plasma of animals 
immunised with whole venom(s) and contain antibodies against snake venom toxins, but also against 
other antigens. In order to better understand the molecular interactions between antivenom antibodies 
and epitopes on snake venom toxins, a high-throughput immuno-profiling study on all manually 
curated toxins from Dendroaspis species and selected African Naja species was performed based on 
custom-made high-density peptide microarrays displaying linear toxin fragments. By detection of 
binding for three different antivenoms and performing an alanine scan, linear elements of epitopes 
and the positions important for binding were identified. A strong tendency of antivenom antibodies 
recognizing and binding to epitopes at the functional sites of toxins was observed. With these results, 
high-density peptide microarray technology is for the first time introduced in the field of toxinology 
and molecular details of the evolution of antibody-toxin interactions based on molecular recognition of 
distinctive toxic motifs are elucidated.
Snakebite envenoming is a much neglected tropical health condition, affecting more than 2.5 million victims per 
year in mainly rural settings across the poorest regions of the World1. Parenteral administration of antivenom has 
since its development in the 1890’s constituted the only effective treatment for snakebite envenomings2. One of 
the reasons for the paucity of breakthrough innovations in the field of antivenom research and development may 
be that snake venoms are among the most complex drug targets known, owing to their great biochemical diver-
sity1,3. Moreover, antivenoms are complex medicines, consisting of polyclonal mixtures of immunoglobulins or 
fragments thereof, which are produced following traditional protocols involving repeated animal immunisation 
with venoms. During the immunisation process, a diverse pool of antibodies is raised, and these antibodies bind 
to and neutralise toxins and non-toxic components present in the venoms4,5. Despite the clinical importance of 
many snake venoms, little is known about the specific interactions between antivenom antibodies and snake 
venom toxins6,7.
At the venom level, an increasing number of studies, based on proteomics and referred to as “antivenomics”, 
are being performed8,9. These investigations provide valuable information on which venom components are rec-
ognised by antibodies from a given antivenom. Moreover, the antivenomics protocol allows for investigation of 
antivenom para-specificity (i.e. cross-reactivity to snake venom toxins not included in the immunisation mixture) 
and can thereby be used for the rational design, development, and clinical use of antivenoms9,10. Although the 
antivenomics methodology has proven to be a useful tool for descriptive purposes, it does not provide deeper 
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insights into the interactions between toxins and antibodies at the molecular level and thereby explain the origin 
of any observed venom para-specificity.
Studies of snake toxin epitopes have traditionally been performed as time-consuming cross-reactivity experi-
ments on only about a dozen of model toxins, deriving mainly from the group of elapid α -neurotoxins11. Recently, 
studies involving immunoassay quantification of antivenom binding to immobilised synthetic peptides (SPOT 
synthesis), corresponding to individual segments of the amino acid sequence of a given toxin, have added valu-
able molecular insight by elucidating which sequences contain linear elements of epitopes recognised by given 
antivenoms6,7,12–14. These kind of meticulous epitope mapping experiments have also been performed on tox-
ins from Tityus scorpions15–17 and Loxosceles spiders18. The possibility of combining antivenomic assessment 
of antivenoms with a high-throughput epitope mapping approach of snake venom toxins may provide deeper 
insight into toxin-antivenom interactions. Such insight may further be used to understand the basis of antivenom 
specificity and para-specificity, which may guide the development of broad-acting antivenoms with higher effi-
cacy and polyvalence.
In this study, we focused on venom toxins from the four species-membered Dendroaspis (mamba) genus, a 
group of snakes in sub-Saharan Africa of the highest medical importance. Mamba envenomings are known for 
their rapid onset of neurotoxicity19,20, which may manifest itself already after 15 min via clinical signs such as 
flaccid paralysis, dyspnea due to respiratory muscle paralysis, and involuntary skeletal muscle contractions or 
fasciculations19. These effects are explained by the venom compositions, which are dominated by potent small 
neurotoxins belonging to the three-finger toxin family and Kunitz-type serine protease inhibitor family21–23. 
α -neurotoxins bind to nicotinic cholinergic receptors at the motor end-plate of muscle fibers, thereby blocking 
neuromuscular transmission24. Dendrotoxins, which belong to the Kunitz-type serine protease inhibitor protein 
family, interact with voltage-dependent potassium channels, leading to excitatory effects due to facilitation of the 
release of acetylcholine and potentiation of its effect at the presynaptic nerve terminal25. In addition, fasciculins, 
which are inhibitors of acetylcholinesterase (AChE), have been isolated from D. angusticeps venom, and these 
quite unique AChE inhibitors may induce increased synaptic concentrations of acetylcholine causing fascicula-
tion26. Although many toxins have been isolated and sequenced from Dendroaspis venoms, only the venoms of 
D. polylepis and D. angusticeps have so far undergone a thorough toxicovenomics analysis21,22. In spite of the 
significant differences in venom compositions, many similar toxins exist in Dendroaspis venoms, although in 
different relative proportions, which is to be expected given the phylogenetic proximity of the four species27.
The present study aims at exploring the binding patterns of three polyvalent antivenoms distributed in 
sub-Saharan Africa, which include mamba venoms as part of their immunizing mixtures, towards the 61 mamba 
venom proteins available in the UniProtKB database28. Using state-of-the art SPOT strategy this would com-
prise the synthesis of 1,026 unique 12-mer peptides. To tackle this challenge, we introduce high-density peptide 
microarray technology29 for the first time in the field of antivenom research. Overlapping 12-mer peptides, cov-
ering the entire primary sequence of each neurotoxin, were prepared by light-directed solid-phase synthesis. 21 
Antivenom Manufacturer Venoms in immunisation
Protein 
concentration
SAIMR Polyvalent South African Dendroaspis angusticeps 171.6 mg/mL
Snake Antivenom Vaccine Producers D. jamesoni
(Pty) Ltd D. polylepis
Naja annulifera
N. melanoleuca
N. mossambica
N. nivea
Bitis arietans
B. gabonica
Haemachatus haemachatus
Snake Venom VINS Bioproducts D. jamesoni 64.4 mg/mL
Antiserum D. polylepis
(African) D. viridis
N. haje
N. melanoleuca
N. nigricollis
B. arietans
B. gabonica
Echis leucogaster
E. ocellatus
Snake Venom VINS Bioproducts D. polylepis 90.5 mg/mL
Antiserum B. gabonica rhinoceros
(Central Africa) Vipera (Daboia) russelli
E. carinatus
Table 1.  Immunisation mixtures for antivenoms used in the study, specified by their manufacturers.
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neurotoxins from three African Naja (cobra) species were also included on the high-density peptide microarray. 
These related neurotoxins were included to address potential convoluted epitope preferences of antivenom result-
ing from inclusion of venom(s) from African cobra snakes in the immunisation mixture for the antivenoms. This 
setup allowed an investigation of antivenom cross-recognition of linear epitopes among the toxins. Moreover, 
mutated versions of 12-mers corresponding to single replacement of each amino acid with alanine (i.e. alanine 
scanning) were additionally included, aiming to identify key residues in epitopes responsible for antibody bind-
ing. This dramatically increased the number of unique synthesised peptides with 20,056.
Results and Discussion
Aiming at comprehensively mapping all epitopic linear elements in the 82 mamba and cobra venom toxins in 
Tables 2 and 3 on the basis of recognition by three therapeutic antivenoms, an approach built upon custom-made 
Snake species UniProt entry Length Protein subfamily Protein sub-subfamily
D. polylepis P25687 81 AVIT (prokineticin)
D. angusticeps P28374 38 Natriuretic peptide
D. angusticeps Q8QGP7 53 Natriuretic peptide
N. melanoleuca P01383 71 Long-chain 3FTx T2-α -NT
N. melanoleuca P01388 71 Long-chain 3FTx T2-α -NT
N. nivea P01390 71 Long-chain 3FTx T2-α -NT
N. haje P25674 71 Long-chain 3FTx T2-α -NT
D. jamesoni P01393 72 Long-chain 3FTx T2-α -NT
D. viridis P01394 72 Long-chain 3FTx T2-α -NT
D. viridis P01395 73 Long-chain 3FTx T2-α -NT
D. polylepis P01396 72 Long-chain 3FTx T2-α -NT
D. polylepis P01397 72 Long-chain 3FTx T2-α -NT
D. polylepis P25667 72 Long-chain 3FTx T2-α -NT
N. melanoleuca P01400 65 Non-conventional 3TFx ORP-II
N. haje P01401 65 Non-conventional 3TFx ORP-II
N. nivea P25680 65 Non-conventional 3TFx ORP-II
D. jamesoni P25682 63 Non-conventional 3TFx ORP-XIX
D. angusticeps C0HJB0 57 Short-chain 3FTx
D. polylepis P0DKR6 78 Short-chain 3FTx
D. polylepis P0DKS3 57 Short-chain 3FTx
D. angusticeps P0C1Y9 61 Short-chain 3FTx FAS
D. angusticeps P0C1Z0 61 Short-chain 3FTx FAS
D. polylepis P25681 61 Short-chain 3FTx FAS
D. angusticeps Q9PS08 30* Short-chain 3FTx FAS
D. jamesoni P01407 62 Short-chain 3FTx AMI
D. angusticeps P01408 63 Short-chain 3FTx AMI
D. angusticeps P01409 63 Short-chain 3FTx AMI
D. angusticeps P01410 62 Short-chain 3FTx AMI
D. angusticeps P01411 62 Short-chain 3FTx AMI
D. angusticeps P17696 86 Short-chain 3FTx AMI
D. angusticeps P18328 86 Short-chain 3FTx AMI
D. polylepis P25518 65 Short-chain 3FTx AMI
D. angusticeps P60234 65 Short-chain 3FTx AMI
D. angusticeps P60235 40* Short-chain 3FTx AMI
D. angusticeps P60236 40* Short-chain 3FTx AMI
D. polylepis P80494 66 Short-chain 3FTx AMI
D. polylepis P80495 65 Short-chain 3FTx AMI
D. angusticeps P81030 66 Short-chain 3FTx AMI
D. angusticeps P81031 65 Short-chain 3FTx AMI
D. angusticeps P85092 65 Short-chain 3FTx AMI
D. angusticeps P86419 66 Short-chain 3FTx AMI
D. angusticeps Q8QGR0 86 Short-chain 3FTx AMI
D. angusticeps Q9PSN1 66 Short-chain 3FTx AMI
Table 2.  Toxins included in the study part 1. Asterisk marks when an entry represents a fragment of the full 
sequence. Abbreviations: 3FTx (Three-finger toxin), T2-α -NT (Type 2 α -neurotoxin), ORP-II (orphan group II 
toxin), ORP-XIX (orphan group XIX toxin), FAS (Fasciculin), AMI (Aminergic toxin).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:36629 | DOI: 10.1038/srep36629
high-throughput peptide microarrays was employed. All antivenoms consisted of F(ab′ )2 fragments obtained 
by pepsin digestion of IgG antibodies from equine serum. The reported immunisation mixtures for the 
hyper-immunised horses are summarised in Table 1. Each antivenom was employed in two different dilutions of 
the original samples, resulting in a total of six peptide microarray experiments.
Peptide microarray experiments conducted with the same antivenom in different dilutions were in good 
agreement with each other, as shown in Fig. 1A–C. In each experiment, the vast majority of peptides were found 
to provide low signal intensities. This is displayed as violin plots in Fig. 1D and it can be seen that the majority of 
peptides have unspecific binding or auto-fluorescence following a normal distribution. Although a smooth tran-
sition is observed between the background signals and signals resulting from putative antibody-binding, it is easy 
to identify peptides with a high signal-to-noise ratio even by visual inspection. Comparing the six violin plots in 
Fig. 1D, it is also evident that the distribution of background signals is not directly comparable among antiven-
oms from different producers (SAVP and VINS Bioproducts). For the SAIMR Polyvalent Snake Antivenom from 
SAVP, much higher signals were observed than for the VINS products (see also Fig. 1A–C). This bias is likely 
due to differences in antivenom formulations and production methods, as well as the concentration of antibody 
fragments in the formulation (see Table 1).
Snake species UniProt entry Length Protein subfamily Protein sub-subfamily
D. jamesoni P01413 61 Short-chain 3FTx ANP
D. jamesoni P28375 59 Short-chain 3FTx ANP
D. angusticeps P81946 59 Short-chain 3FTx ANP
D. polylepis P01414 60 Short-chain 3FTx LTC
D. polylepis P22947 60 Short-chain 3FTx LTC
D. jamesoni P25683 60 Short-chain 3FTx LTC
D. angusticeps P25684 60 Short-chain 3FTx LTC
N. haje P01415 61 Short-chain 3FTx ORP-VI
D. angusticeps P18329 80 Short-chain 3FTx ORP-XI
D. angusticeps P01404 81 Short-chain 3FTx ORP-XI
D. viridis P01405 60 Short-chain 3FTx ORP-XI
D. jamesoni P01406 60 Short-chain 3FTx ORP-XI
D. angusticeps Q9PS09 30* Short-chain 3FTx ORP-XI
N. melanoleuca P01473 61 Short-chain 3FTx ORP-XV
N. melanoleuca P01474 61 Short-chain 3FTx ORP-XV
N. haje P62394 62 Short-chain 3FTx ORP-XV
D. angusticeps P60237 63 Short-chain 3FTx TB-MUS
N. nivea P01423 61 Short-chain 3FTx T1-α -NT
N. melanoleuca P01424 61 Short-chain 3FTx T1-α -NT
N. haje P25675 61 Short-chain 3FTx T1-α -NT
N. haje P68418 61 Short-chain 3FTx T1-α -NT
N. nivea P68419 61 Short-chain 3FTx T1-α -NT
D. polylepis P01416 60 Short-chain 3FTx T1-α -NT
D. jamesoni P01417 60 Short-chain 3FTx T1-α -NT
D. viridis P01418 60 Short-chain 3FTx T1-α -NT
D. jamesoni P01419 58 Short-chain 3FTx T1-α -NT
N. melanoleuca P01448 60 Short-chain 3FTx T1A-CYT
N. nivea P01456 60 Short-chain 3FTx T1A-CYT
N. haje P01457 60 Short-chain 3FTx T1A-CYT
N. nivea P01458 60 Short-chain 3FTx T1A-CYT
N. nivea P01463 60 Short-chain 3FTx T1A-CYT
D. polylepis P00979 60 Kunitz-type
D. angusticeps P00980 59 Kunitz-type
D. polylepis P00981 79 Kunitz-type
D. angusticeps P00982 57 Kunitz-type
D. polylepis P00983 57 Kunitz-type
D. polylepis P00984 59 Kunitz-type
D. angusticeps P0DMJ6 59 Kunitz-type
D. angusticeps P81658 60 Kunitz-type
Table 3.  Toxins included in the study part 2. Asterisk marks when an entry represents a fragment of the full 
sequence. Abbreviations: 3FTx (Three-finger toxin), ANP (antiplatelet toxin), LTC (L-Type calcium channel 
blocker) ORP-VI (orphan group VI toxin), ORP-XI (orphan group XI toxin), TB-MUS (Type B muscarinic 
toxin), T1-α -NT (Type 1 α -neurotoxin), T1A-CYT (Type 1A cytotoxin).
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Key findings within the most important toxin families in mamba and cobra venoms are presented in the 
following subsections, where focus is directed on toxins of high medical importance as judged by their Toxicity 
Scores determined in previous studies21,22.
Mapping of antibody binding reveals antigenic hotspots in toxin sequences. Linear elements 
in epitopes are usually between 7 and 9 amino acid residues in size30,31 implying that a high signal is likely to be 
observed across overlapping 12-mer peptides containing the epitope motif. Applying this principle, signal inten-
sities for each of the peptides were mapped back to the respective toxin sequences from which the peptides were 
derived. By plotting signal intensity as a function of peptide position in the toxin sequence, binding profiles of 
each toxin-antivenom pair were obtained. The binding profiles of the type 1 α -neurotoxins included in the study 
can be found in Fig. 2 for illustration of how peaks in signal intensity, corresponding to areas containing linear 
epitopic elements, are clearly distinguished from the background noise. For each antivenom, two binding profiles 
corresponding to the two separate experiments with different dilutions were obtained. As shown in Fig. 2, the 
two sets of results (coloured blue and red) were found to give similar binding profiles reflecting a high degree of 
reproducibility of results even when the dilutions were altered (Fig. 1A–C). Moreover, the binding profiles for 
the type 1 α -neurotoxins display a general tendency for all three antivenoms to peak around peptide number 25 
(covering the 12 residues from 25 to 36). A more in-depth discussion on the antibody recognition of the type 1 
α -neurotoxins is reserved for a later section. The complete collection of binding profiles for the 82 investigated 
mamba and cobra toxins can be found in Supplementary Figs S1–7.
A high number of binding peptides were identified with SAIMR polyvalent antivenom. The 
numeric size of the signal for a peptide being recognised by the polyvalent antivenoms is a complex function 
of the concentration of one or more specific antibodies, the affinity of each of the antibodies, and the structural 
arrangement and conformation of the peptide on the microarray30. Also, variation in peptide solvation is likely 
to play a role. Regardless of the molecular origin of signals for peptides recognised by antibodies, it is crucial to 
separate them from the noise resulting from unspecific binding and auto-fluorescence. For each experiment, 
putative epitope-containing peptides were identified based on the median signal intensity of each peptide and 
the assumption that the majority of peptides were not recognised by the antibodies. The assumption is based on 
the distribution of all signals (Fig. 1), supported by the presence of clear baselines in the binding profiles (Fig. 2 
and Supplementary Figs S1–7), and it is in agreement with the findings in a previous study with antivenom and 
members of the three-finger toxin protein family12. As a conservative estimate, the lower 70-percentile of median 
signals was used to determine the mean and standard deviations of the background populations, and a peptide 
was classified as target for antivenom antibodies if the median signal intensity was more than 10 standard devia-
tions above the mean (see method section for details).
The overlap between the groups of peptides classified as antibody binders in the individual experiments was 
determined and the outcome is shown as Venn diagrams in Fig. 3. For microarrays with the same antivenom in 
different dilutions, the majority of the identified binders is shared within the data sets. Experiments employing 
the SAIMR polyvalent antivenom at two different dilutions displayed the highest degree of agreement between 
two experiments with only 12% non-shared peptides, while the number of non-shared peptides were 26% and 
20% for for VINS African antivenom and VINS Central Africa antivenom, respectively (Fig. 3A–C). The two 
VINS antivenoms were found to be relatively similar in their recognition of the peptides, although VINS African 
antivenom recognises a higher number of peptides than VINS Central Africa antivenom (Fig. 3D). Based on 
the reported immunisation mixtures in Table 1, the broader recognition of peptides from elapid toxins by VINS 
African compared to VINS Central Africa is in agreement with the broader range of venoms that the antivenom 
is raised against (Table 1).
Considering only the peptides displaying antibody binding at both concentrations for each antivenom, a con-
siderable fraction consisting of 58 unique peptides was found to be recognised by all three antivenoms. Also, 
only 19 unique peptides were found to bind one or both of the VINS antivenoms and not the SAIMR antivenom 
(Fig. 3D). In fact, the SAIMR antivenom was found to bind four times as many peptides as the two antivenoms 
from VINS Bioproducts. Also, binding was observed between the SAIMR antivenom and one or more pep-
tides for 80 out of the 82 toxins included in the study. Only the two short chain three-finger toxins, Weak toxin 
CM-2 (P01415) from N. haje and a fragment of Muscarinic m1-toxin3 (P60235) from D. angusticeps, were not 
recognised.
Due to the low number of peptides recognised exclusively by the VINS antivenoms and the more distinct 
signals in the microarrays loaded with SAIMR antivenom, the epitope characterisation in the following sections 
is based on the results from the SAIMR antivenom only.
Alanine substitution analysis reveals key residues for antivenom toxin recognition. For all 
12-mers classified as antibody-binding peptides, the decrease or increase in signal intensity of replacing each 
residue for alanine was determined. This had the goal of identifying residues of importance for the antibody-toxin 
interaction, as the substitution for alanine is thought to be a good model for removing single functionalities, one 
at a time, from a given peptide. An average alanine substitution effect was calculated for each amino acid, taking 
the substitution effects at multiple positions in the 12-mer setup into account. This means that, when an amino 
acid is present on multiple overlapping antibody-binding 12-mers, the effect of the position of the residue in each 
single peptide (e.g. in the C-terminal or N-terminal part) is reduced.
As the average alanine substitution effect of a given residue is a relative number, it does not reflect the size of 
the original signal intensities. Therefore, the binding profiles (Fig. 2 and Supplementary Figs S1–7) were config-
ured to be a function of the amino acid sequences rather than the position of 12-mer peptides. This was done by 
calculating a complementary “residue score” as the average signal intensity of the consecutive 12-mer peptides 
www.nature.com/scientificreports/
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in the toxin containing that given residue. In contrast to the calculation of a residue-specific alanine substitution 
effect, all available peptides spanning the residue when mapped to the protein sequence were used for determin-
ing the residue score.
Several of the toxins included in the experimental setup are homologs of each other and are therefore identical 
in parts of their sequences. To reduce the complexity in the data, the related sequences are aligned, so that the 
mentioned residues are displayed below each other. Also, such representation of the results allows visualisation 
of the effects of minor variations between similar toxins. The results for each protein subfamily are presented and 
discussed in the following sections with an emphasis on selected three-finger toxins and dendrotoxins, whereas 
the results for other toxins can be found in the Supplementary Fig. S8.
Short chain subfamily of the three-finger toxins. The study includes 55 members of the short chain subfamily 
belonging to 11 different protein sub-subfamilies. The identified key motifs for antibody-binding were found 
to be protein sub-subfamily specific with epitopes across all three loops and the N-terminal of the short chain 
three-finger toxins (Fig. 4).
One of the most important toxin groups contributing to the high lethality of the venoms of many elapids, 
including D. polylepis, is the short chain (type 1) α -neurotoxins22, of which four originate from mamba and five 
from cobra species. For this group of α -neurotoxins, the most noticeable residue scores and effects of substitution 
for alanine were observed for the motif DHRG found in the alignment from position 34 to 37. All the residues in 
DHRG are found in loop 2 of the three-finger structure (Fig. 5A,B), wherein Arg36 is known to be particularly cru-
cial for the interaction between α -neurotoxins and their targets, the neuromuscular nicotinic acetylcholine recep-
tors (nAChRs)27,32. Furthermore, it is noteworthy that an area covering loop 1 also seems to be recognised by the 
antivenom antibodies for all four mamba toxins in this sub-subfamily, although the residue scores in this region 
are lower than for the DHRG motif. This area has been reported to be important for the interaction with carbo-
hydrate moieties (glycosylations) on the nAChR32. The charged and polar residues in the type 1 α -neurotoxins, 
including Lys15, seem to be important for the recognition of mamba toxin epitopes (see Figs 4 and 5). 
Even though Lys15 is also found in the five similar cobra toxins, the variation in the surrounding residues is likely 
to cause their observed lack of antibody binding. The most notable differences between this region of the mamba 
and cobra type 1 α -neurotoxins is Pro12 and Pro18 in the cobra toxins, which are respectively replaced with ala-
nine or simply excised in the mamba toxins. These differences might explain why the SAIMR antivenom has a 
preference for loop 1 in mamba type 1 α -neurotoxins over the equivalent cobra toxins. The therapeutic relevance 
of this difference may, however, be limited if antibody binding to the DHRG motif is sufficient to neutralise the 
toxic effects of all the toxins in this protein sub-subfamily.
The SAIMR antivenom is produced using venoms, which contain six of the nine type 1 α -neurotoxins 
included in this study (see markers in Fig. 4 left of each sequence). However, the three toxins from the venoms of 
D. viridis and N. haje were also found to bind the antivenom antibodies via parts of their sequences shared with 
the toxins included in the immunisation. This indicates the possible presence of para-specificity for the SAIMR 
Figure 1. Correlation between experiments with the same antivenom used in different dilutions show 
a high degree of reproducibility and agreement between the microarray experiments. The correlation of 
median signal intensities of five replicates of each peptide is plotted for each pair of experiments conducted 
with the same antivenom. (A) SAIMR Polyvalent Snake Antivenom, (B) VINS African, and (C) VINS Central 
Africa. (D) Violin plots illustrating the distribution of peptide-specific median signals below 250 AU for each 
experiment.
www.nature.com/scientificreports/
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antivenom towards the investigated D. viridis and N. haje type 1 α -neurotoxins, despite the absence of venoms 
from these species in the immunisation mixture.
Fasciculins are another medically important subfamily of short chain three-finger toxins found primarily 
in D. angusticeps venom21,23. As venom from D. angusticeps is included in the immunisation mixture for the 
SAIMR antivenom, the detected epitopes are likely to be a result of specific antibodies. From co-crystallisation 
of fasciculin-2 (P0C1Z0) with the AChE enzyme, the binding site of fasciculin-2 to the enzyme has been found 
to mainly include the residues from positions 6–12 (in loop 1) and 27–37 (in loop 2)33. In this study, we find high 
residue scores for residues in exactly these two parts of the toxins. Using the crystal structure of fasciculin-2 for 
mapping of residue scores and alanine substitution effects reveals the presence of a connected structural epitope 
as the residues His6 and Thr8 are found in close proximity to the Leu35 and Gly36 in the protein model in Fig. 5C,D.
The experimental setup included four members of the L-type calcium channel blocker subfamily of toxins, 
all originating from mamba snakes. Figure 4 shows that the SAIMR antivenom recognises the longest fully con-
served region between these four toxins, covering residues from Arg42 to Thr58. The residues between Pro49 and 
Gln57 (Met52 to Tyr56 in particular) are found to be critical for toxin and antivenom interaction. It is of particular 
interest that the identified binding motif MWPY in position 52 to 56 is previously described to be the Ca2+ chan-
nel binding site of this toxin group34.
The alanine substitution effect and the residue scores are presented in three dimensions in Fig. 5E,F, exploiting 
the structure of Toxin FS-2 (P01414) for which an experimental NMR structure is available35. From this render-
ing, it is revealed that the two distinct antibody-binding areas found on the primary sequence of the toxin are 
located in two loop structures situated close to each other. It is therefore possible that these represent one epitope 
containing two discontinuous linear elements where one of them is barely detectable and mainly revealed in the 
alanine substitution analysis (Fig. 5E,F). Still, this hypothesis has yet to be validated experimentally.
The examples above with the toxin families known to play major roles in toxicity, illustrate how antibody 
recognition of each toxin sub-subfamily can be explored in detail. The results for 40 additional short chain 
three-fingered toxins are available in Fig. 4, including 19 aminergic (muscarinic) toxins known to act syner-
gistically21. However, a further exploration of these antivenom-toxin interactions is beyond the scope of this 
communication.
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Figure 2. Binding profiles of nine type 1 α-neurotoxins (a subfamily of the short chain three-finger toxin 
subfamily). The median signal intensity of five replicates of each peptide is plotted as dots based on the position 
of the N-terminal residue of the 12-mer peptide in the protein sequences (pro-peptides removed). The dots are 
connected with straight lines to visualise the relation between overlapping peptides. The error bars represent 
the standard deviation of the five replicates. Positions containing gaps in the alignments were ignored. Blue dots 
refer to the 1:50 dilution experiment, while red dots refer to the 1:100 dilution experiments. Notice that many 
12-mer peptides are present in several individual toxin entries and that each point contains information on the 
following 11 amino acids of the toxin. Binding profiles of all 82 toxins in this study are found in Supplementary 
Figs S1–S7.
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Long chain neurotoxins of the three-finger toxin family. All ten long chain three-finger toxins included in the 
study are type 2 α -neurotoxins. Similar to type 1 α -neurotoxins, type 2 α -neurotoxins are inhibitors of neu-
romuscular nAChRs32. Six of the ten type 2 α -neurotoxins originate from mamba species and four from cobra 
species. The effect of alanine substitutions and residue scores were mapped to the aligned protein sequences, 
illustrated in Fig. 6.
The majority of the residues important for antibody-toxin binding are located in loop 2 (position 22 to 42 in 
the alignment), loop 3 (position 47 to 58), and in the C-terminal. This pattern surprisingly differentiates itself 
from the binding pattern observed for type 1 α -neurotoxins (Fig. 4), where linear parts of epitopes were identified 
in loop 1 and 2. The key residues found in the alanine scans are scattered over a large section of the toxins with no 
short distinctive motifs, although residues in position 30 to 36 and 45 to 56 seem to be slightly more important for 
antibody recognition for most long chain α -neurotoxins. The observed binding across two large toxin segments 
could potentially indicate that a mixture of antibodies binding to overlapping epitopes are present in the SAIMR 
antivenom, given that the binding region of an antibody is usually limited to around nine residues30. Nevertheless, 
a number of residues including Gln33, Lys36, Gly52, Val53, and Ile54 seem important in most of the epitopes. The 
spatial distribution of the most important residues is illustrated in Fig. 5G,H.
It is noteworthy that although type 1 and type 2 α -neurotoxins target the same receptor, no similar epitope is 
identified. We therefore hypothesise that no or very little antibody cross-recognition takes place between the two 
types of α -neurotoxins. This implies that even though the clinical manifestations of a snakebite might include 
flaccid paralysis from abrogation of neuromuscular transmission due to the effects of α -neurotoxins, it is crucial 
for an efficacious antivenom to recognise and neutralise the specific subtype of α -neurotoxins present in the 
venom of the snake species responsible for the bite.
The residues of type 2 α -neurotoxins involved in nAChR inhibition have been investigated for a limited num-
ber of toxins, including α -bungarotoxin from Bungarus multicinctus36,37 and α -elapitoxin-Nno2a from Naja naja 
oxiana38. These studies uncovered interactions between the neuromuscular nAChR and all three loops of the 
three-finger structure of the toxins, thus involving a high number of interacting residues. For α -bungarotoxin, 34 
out of 74 residues were involved in binding. All but one of the residues found to be important for antibody rec-
ognition in the mamba toxins corresponded to the very same residues found to be important in α -bungarotoxin 
interaction with the nAChR. The only exception is Gly52, which was not part of the interaction for α -bungarotoxin 
although it is located in loop 2 (Fig. 5G,H). However, this small amino acid may be important for conformational 
flexibility required to position the loops appropriately for antibody (and perhaps also receptor) binding for the 
mamba toxins.
For most type 2 α -neurotoxins, binding between the SAIMR antivenom and two or more non-overlapping 
12-mers classified as antibody binders was observed, even though three of the toxins originate from snake spe-
cies not included in the SAIMR immunisation mixture. This para-specificity can be explained by the presence 
of completely conserved sections between these three toxins and the mamba and cobra toxins included in the 
immunisation mixture. On the other hand, for sub-sequences, where amino acids are substituted, para-specificity 
can easily be lost. This is illustrated by the C-terminal of α -elapitoxin-Dv2b (P01394) from D. viridis, which is not 
recognised by the antivenom at all (see Fig. 6), although only two amino acids (Asp64, Lys69) are altered compared 
to α -elapitoxin-Dv2a (P01395), also from D. viridis. This example illustrates that high similarity is not sufficient 
to predict antibody binding if the key residues for the interaction are not known.
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Figure 3. (A–C) Venn diagrams of peptides classified to bind antivenom antibodies for each pair of 
experiments conducted with the same antivenom in two different dilutions; (A) SAIMR Polyvalent Snake 
Antivenom, (B) VINS African, and (C) VINS Central Africa. (D) Venn diagram of peptides classified as binders 
for each antivenom. Only peptides identified in both experiments with each antivenom, corresponding to the 
overlap in Venn diagram in part A–C, are included.
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Dendrotoxins of Kunitz-type inhibitor family. The study included eight dendrotoxins from D. polylepis and 
D. angusticeps (Fig. 7). In each case, at least three overlapping antibody-binding 12-mer peptides were iden-
tified in position 37 to 52, in which particularly Phe47 was found to be crucial for antibody recognition in all 
cases. Based on residue scores observed in this region, the eight dendrotoxins can be divided in two distinct 
groups. The high scoring toxins differed from the low scoring toxins in position 44 and 48, where Ala44 and 
Lys48/Gln48 (high scoring toxins) were replaced with a serine in one of the positions. The four dendrotoxins 
showing decreased antibody-binding for residues between position 37 to 52 do, however, all display a weak but 
shared epitope PAFYYN in alignment position 21 to 26. The Pro21, Phe23, and Asn26 seem particularly impor-
tant in the alanine substitution analysis, although the replacement of Ala22 with serine completely abrogates 
antibody binding to the epitope. This variability within dendrotoxins containing Ala or Ser in similar positions 
(Ala and Ser codons are only one base pair apart) is likely to have major consequences in terms of immu-
nogenicity and cross-recognition of the raised antibodies in an antivenom. This may explain the previously 
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Figure 4. B-cell epitope analysis of the short chain subfamily of three-finger toxins recognised by the 
SAIMR polyvalent antivenom. The filled profiles above each sequence represent the residue scores. The tile 
background represents the average alanine substitution effect. The effect is displayed in log2 fold-change for 
residues present in peptides classified as epitope-containing peptides (see text for details). When no 12-mer 
peptide covering a given residue passed the epitope-threshold, the residue is coloured gray. Dark purple 
indicates that a residue is of particular importance for antibody recognition. The abbreviations after each toxin 
entry refers to the protein sub-subfamilies as given in Tables 2 and 3.
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observed absence of significant binding in an ELISA experiments to one of the dendrotoxin-containing venom 
fractions from D. polylepis, where the very same antivenom was employed21.
Antivenoms tend to bind to functional sites of toxins. The relative number of epitopes containing 
sufficiently large linear elements to be identified in this peptide microarray setup is unknown and not addressed 
here. Therefore, it is theoretically possible that the corresponding antibodies are not those that protect a vic-
tim from the consequences of snakebite envenoming. However, the binding data presented above highlights an 
Figure 5. Structural presentation of B-cell epitope analysis. (A,B) Short neurotoxin 1 (P01416) from D. polylepis  
as an example of a type 1 α -neurotoxin. Structure built upon54; (C,D) Fasciculin-2 (P0C1Z0) from D. angusticeps  
as an example of a fasciculin. The Fasciculin-2 is co-crystallised with the human acetylcholinesterase enzyme. 
Structure built upon55; (E,F) Toxin FS-2 (P01414) from D. polylepis as an example of an L-type calcium channel 
blocker. Structure built upon35; (G,H) Alfa-elapitoxin-Dpp2c (P01397) from D. polylepis as an example of a type 
2 α -neurotoxin. Structure built upon56. (A,C,E,G) Residues coloured according to alanine substitution effect in 
log2 fold-change, where magenta indicates that a residue is of particular importance for antibody recognition. 
Residue numbers refer to original sequence and not alignment; (B,D,F,H) Residues coloured according to 
residue score, where dark red refers to resides with high residue score, and blue refers to residues with low 
residue scores.
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Figure 6. Linear B-cell epitope analysis of ten long chain subfamily three-finger toxins recognised by the 
SAIMR antivenom. See Fig. 4 and text for details.
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intriguing finding. For most of the toxins, the epitopes tend to coincide with the site involved in toxin function. 
A similar finding was recently reported for the binding of camelid single-domain antibody fragments to two 
phospholipases A2 from Bothrops jararacussu venom39. From an evolutionary perspective, toxins have evolved 
to subdue prey and deter predators by specifically targeting essential receptors and enzymes, while remaining 
inert in terms of molecular interactions with other biomolecules3,27,40. Thus, the site involved in toxin function 
contains a distinctive motif capable of engaging in strong interactions based on supramolecular recognition, 
whereas the rest of the toxin molecule may have evolved to engage in as few molecular interactions as possible. 
On speculative grounds, it may be conceived that the emergence of ‘toxic motifs’ from the conserved scaffolds 
of proteins having normal physiological roles in snakes implies evolutionary structural novelty. Therefore, 
novel functional sites in the proteins recruited in venoms to become toxins may not commonly find close 
homologs in immunised animals, which would possibly focus the adaptive humoral response of the animals 
toward such functional sites. Possibly, the distinctive motifs of the functional sites of toxins not only allow 
high affinity interactions to take place between toxin and target, but also between antivenom antibodies and 
toxins, although it is very likely that any small neurotoxin (7–9 kDa in size) would theoretically be neutral-
ised regardless of binding site when encountered by a much larger F(ab′ )2 (100 kDa) or IgG (150 kDa). Given 
that the investigated antivenoms have been shown to recognise and neutralise mamba toxins21,22, the recog-
nition of epitopes at the functional site of the toxins may explain the molecular basis for toxin neutralisation 
through abrogation of toxin-target interaction. This elucidation of epitope-paratope couples may be employed 
to advance our understanding of how the immune systems of production animals select and target antigens 
during immunisation. In turn, this knowledge can be used to optimise and balance serum-based antivenoms 
through engineering of immunisation mixtures to enhance the antibody response against weakly immuno-
genic, yet medically important toxins41, such as dendrotoxins22.
Conclusion
With this study, high-density peptide microarray technology is for the first time exploited for identification 
of linear epitope elements in snake venom toxins. The results obtained clearly demonstrate the power of this 
high-throughput approach compared to similar methods based on SPOT synthesis6,7,12 and mutation analysis11. 
Furthermore, toxin epitopes recognised by antivenom antibodies were unveiled for all but two of the manually 
curated toxins from every mamba and four cobra species endemic to sub-Saharan Africa. These findings also 
point towards the existence of a correlation between the active/functional site of snake venom neurotoxins and 
the site recognised by antivenom antibodies.
The potential of harnessing high-density peptide microarrays for identification of important toxin epitopes 
involved in toxin function and neutralisation by antivenoms may be utilised for design of next generation 
antivenoms based on DNA immunisation and immunisation with synthetic epitope strings13. DNA immunisa-
tion has been explored by a number of research groups42–47, as has the use of synthetic epitope strings in the field 
of spider and scorpion antivenoms48. The possible benefits of using DNA immunisation methods or synthetic 
epitope strings for immunisation include the independence of snake venoms and the ability to select only the 
medically important toxins for the immunisation process. Snake venoms are both expensive and time consum-
ing to procure, and they may be a source for antivenom batch-to-batch variation due to differences in venom 
composition for individual snakes49. Therefore, identification of key epitopes for medically important snake tox-
ins may provide a new avenue towards less expensive antivenoms based on DNA immunisation or synthetic 
epitopes strings with better therapeutic value due to a well-balanced antibody response against important venom 
components.
Finally, the immuno-profiling approach presented here may represent a novel method for assessing 
para-specificity of both antivenoms, individual antibodies, and oligoclonal antibody mixtures. High-density pep-
tide microarrays could thus potentially be used as an indicative high-throughput predictor of what venoms and 
toxins a given antivenom (or antibody) may be able to neutralise.
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Figure 7. Linear B-cell epitope analysis of eight dendrotoxins recognised by the SAIMR antivenom. See 
Fig. 4 and text for details.
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Methods
High-density peptide microarray design. A peptide library was generated in silico for synthesis 
on high-density peptide microarrays. The library consisted of overlapping 12-mers representing the primary 
sequence of the snake neurotoxins listed in Tables 2 and 3 tiled at every second amino acid. All (562) redundant 
(non-unique) peptides were removed and the remaining 1,588 peptides were replicated five times. Furthermore, 
the in silico library was expanded to include peptides representing all possible point mutations to alanine, gener-
ated from each unique peptide. The 18,468 unique alanine substitution peptides were included in one replicate 
resulting in a library of 26,408 peptides in total. Finally, the individual peptides in the library were assigned ran-
dom positions on the microarray in order to minimise the impact of local intensity biases.
High-density peptide microarray synthesis. Six identical microarrays were synthesised with a 
Roche-NimbleGen Maskless Array Synthesiser (MAS) by light-directed solid-phase peptide synthesis using an 
amino-functionalised surface coupled with a 6-aminohexanoic acid linker and amino acid derivatives carrying a 
photosensitive 2-(2-nitrophenyl)propyloxycarbonyl (NPPOC) protection group. Amino acid coupling was per-
formed in dimethylformamide (DMF) for 3 minutes using amino acids pre-activated with HBTU as an activator, 
hydroxybenzotriazole (HOBt) to suppress racemisation, and N,N-diisopropylethylamine as base. Following each 
coupling step, the microarray was washed with N-methyl-2-pyrrolidone (NMP), and site-specific cleavage of the 
NPPOC protection group was accomplished by irradiation of an image created by a Digital Micro-Mirror Device 
(Texas Instruments, SXGA+ graphics format), projecting 365 nm wavelength light. Coupling cycles were repeated 
to synthesise the full in silico generated peptide library. Final removal of side-chain protection groups was per-
formed with 95% trifluoroacetic acid/4.5% water/0.5% triisopropylsilane for 30 minutes.
Antivenoms. Three polyspecific antivenoms were investigated: (a) SAIMR (South African Institute for 
Medical Research) Polyvalent Snake Antivenom from South African Vaccine Producers (Pty) Ltd. (batch num-
ber BC02645, expiry date 07/2016); (b) Snake Venom Antivenom (Central Africa) from VINS Bioproducts Ltd. 
(batch 12AS13002, expiry date 04/2017); and (c) Snake Venom Antivenom (African) from VINS Bioproducts 
Ltd. (batch 13022, expiry date 01/2018). All of them are of equine origin and consist of F(ab′ )2 fragments obtained 
by pepsin digestion of antibodies. The reported immunisation mixtures of the horses are summarised in Table 1. 
Protein concentrations for the antivenoms were measured by their absorbance at 280 nm on a NanoDrop 2000c 
instrument, Thermo Scientific.
Sample binding and processing. The microarrays were incubated overnight at 4 °C with individual 
antivenom samples mixed with binding buffer at either 1:50 or 1:100 dilution to a final volume of 100 μL. This was 
followed by three 10 minute washes with a TBST (Tris Buffered Saline and Tween 20) buffer and incubating with 
goat anti-horse IgG (H+ L) conjugated with Alexa Flour® 647 (Jackson ImmunoResearch, 108-605-003) at room 
temperature for 3 hours. After a final wash, the arrays were dried and read using an MS200 microarray scanner, 
and signals were extracted using NimbleGen DEVA signal extraction software
Clasification of peptides as antibody-binders. The 1,588 unique peptides derived from the orig-
inal toxin sequences (the non-alanine substituted) were each present in five replicates in each microarray. 
The median signal intensities were determined and used to classify peptides as either antibody-binding or 
non-antibody-binding. This classification was performed on the basis of the lower 70-percentile of the median 
signals, as this subset of peptides were assumed to originate from unspecific binding. The lower 70-percentile 
was chosen over other (more or less conservative) percentiles as the resulting distributions of signals closely 
resembled normal distributions (data not shown). For each microarray experiment, the mean and the standard 
deviation of the subsets representing non-specific binding was determined (Supplemental Table S1) and a peptide 
was classified as an antibody target if the median signal intensity was more than 10 standard deviations above the 
mean.
Venn diagrams showing the overlap of the peptides classified as antibody-binders were constructed using R 
package VennDiagram50.
Alanine substitution analysis. The alanine substitution analysis was performed using two custom-built 
Perl programs. The first program went through all possible 12-mer peptides derived from an input fasta file. The 
signal intensities of each peptide were stored as arrays in a hash structure with the peptide sequences serving 
as keys. When a peptide was found to have a median signal intensity above the experiment-specific threshold 
defined above, the signal intensities of the alanine substituted peptides were located in the hash structure. For 
each peptide, an array containing the relative effect of replacing each position for alanine was built and written to 
an output file used for the second custom-built program. For non-antibody-binding peptides, the relative alanine 
substitution effect was not assigned.
The second program was designed to loop over each protein entry and add the generated alanine substitution 
data and median signal data to two separate arrays, where each array element represents an amino acid residue 
in the original protein sequence. Using two other arrays to count the number of times data was added to each 
residue, the average alanine substitution effect of each residue and the average median signal of peptides contain-
ing a given residue (referred to as residue score) were determined. The resulting scores were written to an output 
tab-separated file, which was imported in R for data visualisation using the ggplot2 package51.
All the programs built for this study were prepared to handle gap characters (− ). This feature enables the 
alignment of protein sequences in the input fasta file and generation of figures, such as Fig. 4. Here, Clustal 
Omega was used for multiple sequence alignment52.
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Protein modeling. The residue scores and the average alanine substitution effect of each residue were 
mapped to available protein structures by modifying the temperature factors on the relevant pdb files using the R 
package Rpdb53. All images were generated using an open source built version of The PyMOL Molecular Graphics 
System.
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